Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis

Amir Lerman, Brooks Sayre Edwards, J. W. Hallett, D. M. Heublein, S. M. Sandberg, John C Jr. Burnett

Research output: Contribution to journalArticle

894 Citations (Scopus)

Abstract

Background. Atherosclerosis is characterized by endothelial injury and the proliferation of arterial smooth-muscle cells. The latter may be a result of the release of growth factors from the vessel wall; such growth factors may include an endothelium-derived vasoconstrictor peptide with mitogenic properties. We tested the hypothesis that plasma endothelin concentrations are elevated in persons with symptomatic atherosclerosis, independently of age. Methods. We measured plasma endothelin levels in 100 normal subjects and in 40 patients with atherosclerosis predominantly of the following types: aortic and peripheral vascular disease (14 patients), renovascular disease (9 patients), coronary artery disease (9 patients), and carotid disease (8 patients). We also performed immunohistochemical staining for endothelin in the walls of atherosclerotic vessels. Results. In the normal subjects, the mean (±SD) plasma endothelin concentration was 1.4±0.2 pmol per liter, with no correlation between age and plasma endothelin concentration (r = 0.13, P = 0.2). In the patients with symptomatic atherosclerosis, the mean plasma endothelin concentration was 3.2±1.2 pmol per liter (P<0.001), and there was a significant correlation between plasma endothelin and the number of sites of disease involvement (r = 0.89, P<0.001). In the immunohistochemical studies, endothelin-1-like immunoreactivity was observed in vascular smooth muscle as well as in endothelial cells. Conclusions. Endothelin may be a market for arterial vascular disease. Whether it participates in the atherogenic process or is merely released from damaged endothelial cells is unclear.

Original languageEnglish (US)
Pages (from-to)997-1001
Number of pages5
JournalNew England Journal of Medicine
Volume325
Issue number14
StatePublished - 1991

Fingerprint

Endothelins
Atherosclerosis
Intercellular Signaling Peptides and Proteins
Endothelial Cells
Peripheral Vascular Diseases
Vasoconstrictor Agents
Endothelin-1
Vascular Diseases
Vascular Smooth Muscle
Smooth Muscle Myocytes
Endothelium
Coronary Artery Disease
Staining and Labeling
Peptides
Wounds and Injuries

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. / Lerman, Amir; Edwards, Brooks Sayre; Hallett, J. W.; Heublein, D. M.; Sandberg, S. M.; Burnett, John C Jr.

In: New England Journal of Medicine, Vol. 325, No. 14, 1991, p. 997-1001.

Research output: Contribution to journalArticle

@article{5bb9c4f741754577bcd38970c4084561,
title = "Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis",
abstract = "Background. Atherosclerosis is characterized by endothelial injury and the proliferation of arterial smooth-muscle cells. The latter may be a result of the release of growth factors from the vessel wall; such growth factors may include an endothelium-derived vasoconstrictor peptide with mitogenic properties. We tested the hypothesis that plasma endothelin concentrations are elevated in persons with symptomatic atherosclerosis, independently of age. Methods. We measured plasma endothelin levels in 100 normal subjects and in 40 patients with atherosclerosis predominantly of the following types: aortic and peripheral vascular disease (14 patients), renovascular disease (9 patients), coronary artery disease (9 patients), and carotid disease (8 patients). We also performed immunohistochemical staining for endothelin in the walls of atherosclerotic vessels. Results. In the normal subjects, the mean (±SD) plasma endothelin concentration was 1.4±0.2 pmol per liter, with no correlation between age and plasma endothelin concentration (r = 0.13, P = 0.2). In the patients with symptomatic atherosclerosis, the mean plasma endothelin concentration was 3.2±1.2 pmol per liter (P<0.001), and there was a significant correlation between plasma endothelin and the number of sites of disease involvement (r = 0.89, P<0.001). In the immunohistochemical studies, endothelin-1-like immunoreactivity was observed in vascular smooth muscle as well as in endothelial cells. Conclusions. Endothelin may be a market for arterial vascular disease. Whether it participates in the atherogenic process or is merely released from damaged endothelial cells is unclear.",
author = "Amir Lerman and Edwards, {Brooks Sayre} and Hallett, {J. W.} and Heublein, {D. M.} and Sandberg, {S. M.} and Burnett, {John C Jr.}",
year = "1991",
language = "English (US)",
volume = "325",
pages = "997--1001",
journal = "New England Journal of Medicine",
issn = "1533-4406",
publisher = "Massachussetts Medical Society",
number = "14",

}

TY - JOUR

T1 - Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis

AU - Lerman, Amir

AU - Edwards, Brooks Sayre

AU - Hallett, J. W.

AU - Heublein, D. M.

AU - Sandberg, S. M.

AU - Burnett, John C Jr.

PY - 1991

Y1 - 1991

N2 - Background. Atherosclerosis is characterized by endothelial injury and the proliferation of arterial smooth-muscle cells. The latter may be a result of the release of growth factors from the vessel wall; such growth factors may include an endothelium-derived vasoconstrictor peptide with mitogenic properties. We tested the hypothesis that plasma endothelin concentrations are elevated in persons with symptomatic atherosclerosis, independently of age. Methods. We measured plasma endothelin levels in 100 normal subjects and in 40 patients with atherosclerosis predominantly of the following types: aortic and peripheral vascular disease (14 patients), renovascular disease (9 patients), coronary artery disease (9 patients), and carotid disease (8 patients). We also performed immunohistochemical staining for endothelin in the walls of atherosclerotic vessels. Results. In the normal subjects, the mean (±SD) plasma endothelin concentration was 1.4±0.2 pmol per liter, with no correlation between age and plasma endothelin concentration (r = 0.13, P = 0.2). In the patients with symptomatic atherosclerosis, the mean plasma endothelin concentration was 3.2±1.2 pmol per liter (P<0.001), and there was a significant correlation between plasma endothelin and the number of sites of disease involvement (r = 0.89, P<0.001). In the immunohistochemical studies, endothelin-1-like immunoreactivity was observed in vascular smooth muscle as well as in endothelial cells. Conclusions. Endothelin may be a market for arterial vascular disease. Whether it participates in the atherogenic process or is merely released from damaged endothelial cells is unclear.

AB - Background. Atherosclerosis is characterized by endothelial injury and the proliferation of arterial smooth-muscle cells. The latter may be a result of the release of growth factors from the vessel wall; such growth factors may include an endothelium-derived vasoconstrictor peptide with mitogenic properties. We tested the hypothesis that plasma endothelin concentrations are elevated in persons with symptomatic atherosclerosis, independently of age. Methods. We measured plasma endothelin levels in 100 normal subjects and in 40 patients with atherosclerosis predominantly of the following types: aortic and peripheral vascular disease (14 patients), renovascular disease (9 patients), coronary artery disease (9 patients), and carotid disease (8 patients). We also performed immunohistochemical staining for endothelin in the walls of atherosclerotic vessels. Results. In the normal subjects, the mean (±SD) plasma endothelin concentration was 1.4±0.2 pmol per liter, with no correlation between age and plasma endothelin concentration (r = 0.13, P = 0.2). In the patients with symptomatic atherosclerosis, the mean plasma endothelin concentration was 3.2±1.2 pmol per liter (P<0.001), and there was a significant correlation between plasma endothelin and the number of sites of disease involvement (r = 0.89, P<0.001). In the immunohistochemical studies, endothelin-1-like immunoreactivity was observed in vascular smooth muscle as well as in endothelial cells. Conclusions. Endothelin may be a market for arterial vascular disease. Whether it participates in the atherogenic process or is merely released from damaged endothelial cells is unclear.

UR - http://www.scopus.com/inward/record.url?scp=0025940245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025940245&partnerID=8YFLogxK

M3 - Article

C2 - 1886637

AN - SCOPUS:0025940245

VL - 325

SP - 997

EP - 1001

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 1533-4406

IS - 14

ER -